María Fernanda
López Fernández
Complexo Hospitalario Universitario da Coruña
La Coruña, EspañaPublicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario da Coruña (44)
2023
-
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program
European Journal of Haematology, Vol. 111, Núm. 2, pp. 293-299
-
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1
Journal of Thrombosis and Haemostasis
-
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799
2022
-
IX international curse of continuing formation in haemophilia and other congenital coagulopathies. The role of the Laboratory in coagulation disorders. Diagnosis of von Willebrand disease
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, Vol. 33, pp. S12-S14
-
Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency
Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1369-1378
-
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study
Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1106-1114
2021
-
Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)
Scientific Reports
-
Expanding the genetic spectrum of TUBB1-related thrombocytopenia
Blood Advances, Vol. 5, Núm. 24, pp. 5453-5467
-
Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project
Haemophilia, Vol. 27, Núm. 6, pp. 1007-1021
2020
-
Adherence to prophylaxis in adult patients with severe haemophilia A
Haemophilia, Vol. 26, Núm. 5, pp. 800-808
-
BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
European Journal of Haematology, Vol. 104, Núm. 6, pp. 594-601
-
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study
Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 9, pp. 2145-2154
-
Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain
European Journal of Haematology, Vol. 105, Núm. 1, pp. 94-100
2019
2016
-
Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery
Haemophilia, Vol. 22, Núm. 4, pp. e259-e266
-
Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients
Haemophilia, Vol. 22, Núm. 4, pp. e251-e258
-
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study)
Haemophilia, Vol. 22, Núm. 1, pp. 96-102
-
Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: A European survey
Haemophilia, Vol. 22, Núm. 1, pp. 110-120
-
Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey
Haemophilia, Vol. 22, Núm. 5, pp. 739-751
-
Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors
European Journal of Haematology, Vol. 96, Núm. 5, pp. 461-474